What it's for (Indications)
- Fat emulsions are indicated as a source of calories and essential fatty acids for patients requiring parenteral nutrition, typically when oral or enteral nutrition is inadequate, contraindicated, or not possible.
- They are crucial for maintaining nutritional status, preventing and treating essential fatty acid deficiency (EFAD), and supporting metabolic functions in conditions such as severe malnutrition, surgical stress, burns, trauma, and chronic debilitating diseases.
- The provision of intravenous lipids is an integral component of total parenteral nutrition (TPN) regimens, supplying a concentrated source of energy and structural components for cell membranes and various physiological processes.
- Furthermore, they can help reduce the metabolic burden on the glucose-insulin system in patients with glucose intolerance, offering an alternative energy source.
Dosage Information
| Type | Guideline |
|---|---|
| Standard | The dosage of fat emulsion, such as LIPOFUNDIN 20% IV, must be individualized based on the patient's metabolic capacity, energy requirements, clinical condition, body weight, and the overall nutritional plan. It is administered intravenously as part of a total parenteral nutrition (TPN) regimen, typically infused over several hours daily. For adults, typical dosages range from 0.5 to 1.5 g fat/kg/day, not exceeding 2.5 g fat/kg/day, with infusion rates generally not exceeding 0.125 g fat/kg/hour. Pediatric patients, especially neonates and infants, have different requirements and may tolerate higher doses, but careful monitoring of triglyceride levels is essential to prevent fat overload syndrome. Infusion rates must be meticulously controlled and gradually increased, and serum triglyceride levels should be monitored closely, especially at the initiation of therapy and with any dosage adjustments, to ensure adequate clearance (typically keeping serum triglycerides below 400 mg/dL in adults and 200 mg/dL in pediatric patients). |
Safety & Warnings
Common Side Effects
- Adverse reactions associated with fat emulsion administration can range from mild to severe.
- Common side effects include infusion-related reactions such as fever, chills, flushing, headache, nausea, vomiting, dizziness, and mild dyspnea, often resolving with a temporary reduction in infusion rate or discontinuation.
- More serious adverse events encompass hypersensitivity reactions (anaphylaxis, rash, urticaria, bronchospasm), fat overload syndrome (manifested by fever, hepatosplenomegaly, thrombocytopenia, leukocytosis, hyperlipidemia, and impaired liver function), respiratory distress, cyanosis, and coagulation abnormalities.
- Long-term use, particularly in pediatric patients, may be associated with parenteral nutrition-associated liver disease (PNALD) and cholestasis.
- Hyperlipidemia, hyperglycemia, electrolyte disturbances, and aluminum toxicity (from prolonged infusion of solutions containing aluminum) are also potential concerns.
- Other reported effects include increases in liver enzymes (AST, ALT, alkaline phosphatase), bilirubin, and prolonged prothrombin time.
Serious Warnings
- Black Box Warning: **SERIOUS WARNINGS: HYPERSENSITIVITY REACTIONS, FAT OVERLOAD SYNDROME, INFECTION RISK, AND ALUMINUM TOXICITY** Intravenous lipid emulsions, including LIPOFUNDIN 20% IV, carry a risk of serious and life-threatening adverse reactions. Severe hypersensitivity reactions, including anaphylaxis, have been reported. Patients must be closely monitored for signs of allergic response during and after administration. Fat overload syndrome, characterized by fever, hepatosplenomegaly, anemia, leukopenia, thrombocytopenia, coagulopathy, and impaired liver function, can occur, particularly with excessive doses or impaired lipid clearance. Discontinue infusion immediately if these signs develop. The intravenous administration of any parenteral nutrition component, including lipid emulsions, is associated with a significant risk of infection, particularly catheter-related bloodstream infections, which can be life-threatening. Strict adherence to aseptic technique during catheter insertion and maintenance, as well as during solution preparation and administration, is paramount to minimize this risk. Aluminum toxicity is a critical concern, particularly in patients with impaired kidney function and premature neonates, due to the potential accumulation of aluminum from prolonged parenteral nutrition containing lipid emulsions and other components. Aluminum accumulation can lead to bone disease, central nervous system toxicity, and is often fatal in these vulnerable populations. Regular monitoring of aluminum levels may be warranted for long-term parenteral nutrition patients, and use of aluminum-reduced preparations is recommended for at-risk patients.
- Careful clinical and laboratory monitoring is essential throughout fat emulsion therapy.
- Patients receiving fat emulsions should be monitored for signs of hypersensitivity reactions, fat overload syndrome, and metabolic complications.
- Close observation for fever, chills, dyspnea, rash, or changes in vital signs is critical, especially during the initial stages of infusion.
- Patients with impaired lipid metabolism, such as those with renal or hepatic insufficiency, diabetes mellitus, or pancreatitis with hyperlipidemia, require particular caution and close triglyceride monitoring.
- Discontinuation or dose reduction may be necessary if severe hypertriglyceridemia (e.
- g.
- , >400 mg/dL in adults, >200 mg/dL in pediatric patients) occurs.
- As with all parenteral nutrition components, the intravenous administration of fat emulsion carries an inherent risk of infection, particularly catheter-related bloodstream infections.
- Strict aseptic techniques must be followed during preparation and administration to minimize this risk.
- Acute respiratory distress and changes in coagulation parameters, including prolonged prothrombin time and partial thromboplastin time, have been reported; regular monitoring of pulmonary function and coagulation status is advised.
- Fat emulsions, like other parenteral solutions, may contain trace amounts of aluminum.
- Prolonged parenteral administration in patients with renal impairment and premature neonates has been associated with aluminum toxicity, which can manifest as bone disease and central nervous system toxicity.
- Glucose and electrolyte monitoring is also crucial due to potential shifts in metabolic balance.
How it Works (Mechanism of Action)
Fat emulsions, such as LIPOFUNDIN 20% IV, provide a concentrated source of metabolically active energy in the form of long-chain triglycerides (LCTs), which are primarily composed of fatty acids. Upon intravenous administration, these triglycerides are rapidly cleared from the bloodstream, primarily by lipoprotein lipase, which hydrolyzes them into free fatty acids and glycerol. The free fatty acids are then efficiently taken up by various tissues (e.g., muscle, liver, adipose tissue) and oxidized through beta-oxidation in the mitochondria to generate adenosine triphosphate (ATP), serving as a primary energy substrate and sparing protein for tissue synthesis and repair. Additionally, these emulsions supply essential fatty acids (linoleic and alpha-linolenic acids), which are crucial precursors for prostaglandins, leukotrienes, and thromboxanes, vital for cell membrane structure, fluidity, and various physiological functions, including immune response and inflammation. They are essential for preventing and correcting essential fatty acid deficiency (EFAD), a condition characterized by dermatological changes, impaired wound healing, and growth retardation, as the body cannot synthesize these fatty acids de novo.
Commercial Brands (Alternatives)
No other brands found for this formula.